Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$29.22 USD
+0.18 (0.62%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $29.19 -0.03 (-0.10%) 7:58 PM ET
5-Strong Sell of 5 5
B Value B Growth D Momentum B VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 141 - 160 ( 714 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL: Published Study Data Supports ~$100M Pediatric Market Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August 2021 Net Product Revenues; EXPAREL Growth Continues
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July 2021 Net Product Revenues; Highlights from Wedbush Fireside Chat
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2Q21: Recent Weakness Likely Overplays Competitive or COVID Headwinds; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2: EXPAREL Growth Outlook Keeps Long-Term Thesis In-Tact
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Preannounced 2Q Solid Exparel Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2 Preliminary EXPAREL Sales Beat Par for the Course as Growth Continues
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Eurofarma Deal Provides Glimpse into Global Expansion Strategy
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
May 2021 Preliminary Net Product Revenues Tracking Above Consensus
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department